Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?

Adriano Venditti; Robert Peter Gale; Francesco Buccisano; Gert Ossenkoppele

doi:https://doi.org/10.1038/s41375-020-0780-6

Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?

Adriano Venditti, Robert Peter Gale, Francesco Buccisano, Gert Ossenkoppele

Research output: Contribution to journal › Review article › Academic › peer-review

15 Citations (Scopus)

Original language	English
Pages (from-to)	963-965
Number of pages	3
Journal	Leukemia
Volume	34
Issue number	4
DOIs	https://doi.org/10.1038/s41375-020-0780-6
Publication status	Published - 1 Apr 2020

Access to Document

https://doi.org/10.1038/s41375-020-0780-6

Cite this

@article{ddc56879e63049f38b300b065ff8c7b0,

title = "Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?",

author = "Adriano Venditti and {Peter Gale}, Robert and Francesco Buccisano and Gert Ossenkoppele",

year = "2020",

month = apr,

day = "1",

doi = "https://doi.org/10.1038/s41375-020-0780-6",

language = "English",

volume = "34",

pages = "963--965",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "4",

}

Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant? / Venditti, Adriano; Peter Gale, Robert; Buccisano, Francesco et al.
In: Leukemia, Vol. 34, No. 4, 01.04.2020, p. 963-965.

Research output: Contribution to journal › Review article › Academic › peer-review